-

Vetoquinol: 2025 Calendar of Financial Communication

LURE, France--(BUSINESS WIRE)--Regulatory News:

Vetoquinol (Paris:VETO) published its calendar of financial communication for 2025.

January 30, 2025

2024 Annual Sales (after market)

March 20, 2025

2024 Annual results (confcall after market)

April 24, 2025

2025 First quarter sales (after market)

May 22, 2025

Annual shareholders’ meeting

June 6, 2025

Dividend payment

September 11, 2025

2025 First semester results (confcall after market)

October 28, 2025

2025 Third quarter sales (after market)

Next update: Annual Sales 2024, January 30th, 2025 after market close

ABOUT VETOQUINOL

Vetoquinol is a leading international player in animal health, with operations in Europe, the Americas and Asia/Pacific.

Independent and a pure player, Vetoquinol innovates, develops and markets veterinary medicines and non-medicated products for farm animals (cattle, pigs) and pets (dogs, cats).

Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio and acquisitions in high-potential territories ensure hybrid growth for the Group. At June 30, 2024, Vetoquinol employed 2,519 people.

Vetoquinol has been listed on Euronext Paris since 2006 (mnemonic code: VETO).

The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

Contacts

FOR MORE INFORMATION, CONTACT:

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

Vetoquinol

BOURSE:VETO
Release Versions
EnglishFrench

Contacts

FOR MORE INFORMATION, CONTACT:

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

More News From Vetoquinol

Vetoquinol: 2025 Annual Results

LURE, France--(BUSINESS WIRE)--Regulatory News: Commenting on the 2025 fiscal year, Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), stated, “In an extremely volatile environment, Vetoquinol has once again this year demonstrated the resilience of its business model, driven by a long-term strategic vision which, combined with our proactive management of expenses, enables us to deliver a healthy level of profitability. We will actively pursue this strategy, relying in particular on...

Vetoquinol: 2025 Annual Sales

LURE, France--(BUSINESS WIRE)--Regulatory News: In an economy marked by unusual exchange rate volatility, Vetoquinol (Paris:VETO) achieved two important objectives: growth in Essential products and internalization of the manufacturing of the parasiticide range. Vetoquinol's sales for FY 2025 came to €525.7 million, up 0.2% at constant exchange rates and down 2.5% on a reported basis. Over the financial year, the company recorded historically high negative currency impacts of €14.8 million in al...

Vetoquinol: Sales at End September 2025

LURE, France--(BUSINESS WIRE)--Regulatory News: At the end of September 2025, Vetoquinol's (Paris:VETO) sales amounted to €384.2 million, down 3.5% on a reported basis and down 1.3% at constant exchange rates. Over this period, the Group recorded net negative currency impacts of €8.9 million in the Americas and Asia-Pacific/Rest of the World regions and an impact of - €7.7 million from the simplification of complementary ranges, mainly in Europe. Net of these two items, sales for the first nine...
Back to Newsroom